Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 11/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.31 |
| ▸ | PTPRC | P08575 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17345515 | 0.86 | STAT3 (0.48) | STAT3ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL18807114 | 0.85 | STAT3 (0.52) | STAT3ALDH1A1APAF1MITFLMNA | |
| SCHEMBL17345519 | 0.84 | STAT3 (0.53) | STAT3ALDH1A1APAF1MITFLMNA | |
| SCHEMBL17345540 | 0.84 | STAT3 (0.50) | STAT3ALDH1A1APAF1MITFLMNA | |
| SCHEMBL18731231 | 0.83 | STAT3 (0.52) | STAT3ALDH1A1APAF1MITFLMNA | |
| SCHEMBL17345498 | 0.81 | STAT3 (0.56) | STAT3ALDH1A1APAF1MITFLMNA | |
| SCHEMBL17345513 | 0.81 | STAT3 (0.59) | STAT3ALDH1A1APAF1MITFLMNA | |
| SCHEMBL18730823 | 0.81 | STAT3 (0.56) | STAT3ALDH1A1APAF1MITFLMNA | |
| SCHEMBL17345527 | 0.81 | STAT3 (0.49) | STAT3ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL17345514 | 0.80 | STAT3 (0.47) | STAT3ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267797-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-03-08 | — | — | US | disclosed |
| US-20200317630-A1 | ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| US-10689355-B2 | Anticancer agent | Kyoto Pharmaceuticals Industries, Ltd. (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190322636-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-10377730-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2019-08-13 | — | — | US | disclosed |
| US-10005752-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-10005752-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2018-06-26 | — | — | US | disclosed |
| US-20170121299-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20170121299-A1 | NOVEL ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3153508-A1 | NOVEL ANTICANCER AGENT | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2017-04-12 | — | — | EP | disclosed |
| WO-2015190489-A1 | NOVEL ANTICANCER AGENT | 京都薬品工業株式会社 | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121299-A1 | NOVEL ANTICANCER AGENT | NTPCR, TP53, NME1 | STAT3 1231/4885ALDH1A1 187/4885NR4A2 2364/4885 |
| US-20200317630-A1 | ANTICANCER AGENT | TP53, NTPCR, NQO1 | STAT3 1303/4885ALDH1A1 160/4885NR4A2 2789/4885 |
| US-10005752-B2 | Anticancer agent | TP53, NTPCR, NQO1 | STAT3 1303/4885ALDH1A1 160/4885NR4A2 2789/4885 |
| US-11267797-B2 | Anticancer agent | TP53, NTPCR, NQO1 | STAT3 1303/4885ALDH1A1 160/4885NR4A2 2789/4885 |
| US-20190322636-A1 | NOVEL ANTICANCER AGENT | NTPCR, TP53, NME1 | STAT3 1231/4885ALDH1A1 187/4885NR4A2 2364/4885 |
| US-10689355-B2 | Anticancer agent | TP53, NTPCR, NQO1 | STAT3 1303/4885ALDH1A1 160/4885NR4A2 2789/4885 |
| US-10377730-B2 | Anticancer agent | TP53, NTPCR, NQO1 | STAT3 1303/4885ALDH1A1 160/4885NR4A2 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.